Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | PTGES | O14684 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2698809 | 0.85 | NPC1 (0.39) | NPC1ALDH1A1EZH2ALOX5PTGS1 | |
| SCHEMBL2695937 | 0.83 | LMNA (0.42) | NPC1ALDH1A1 | |
| SCHEMBL5525636 | 0.76 | NPC1 (0.39) | NPC1ALDH1A1EZH2ALOX5PTGS1 | |
| SCHEMBL5517552 | 0.75 | LMNA (0.42) | NPC1ALDH1A1 | |
| SCHEMBL2698798 | 0.70 | KDM4E (0.40) | ALDH1A1 | |
| SCHEMBL2697504 | 0.69 | PDGFRB (0.39) | ALDH1A1 | |
| SCHEMBL8685016 | 0.68 | PTGES (0.38) | ALDH1A1ALOX5PTGES | |
| SCHEMBL2699346 | 0.68 | ALDH1A1 (0.41) | NPC1ALDH1A1 | |
| SCHEMBL2697658 | 0.66 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL2697916 | 0.65 | PDGFRB (0.39) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108583-A1 | Tricyclic Compounds As mPGES-1 Inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108583-A1 | Tricyclic Compounds As mPGES-1 Inhibitors | PTGES, PTGS1, PTGIS | NPC1 506/4885ALDH1A1 263/4885EZH2 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.